Edgestream Partners, L.P. Biomarin Pharmaceutical Inc Transaction History
Edgestream Partners, L.P.
- $2.88 Billion
- Q1 2025
A detailed history of Edgestream Partners, L.P. transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Edgestream Partners, L.P. holds 60,632 shares of BMRN stock, worth $3.59 Million. This represents 0.15% of its overall portfolio holdings.
Number of Shares
60,632
Previous 144,996
58.18%
Holding current value
$3.59 Million
Previous $9.53 Million
55.03%
% of portfolio
0.15%
Previous 0.42%
Shares
9 transactions
Others Institutions Holding BMRN
# of Institutions
665Shares Held
185MCall Options Held
1.24MPut Options Held
957K-
Black Rock Inc. New York, NY22.7MShares$1.35 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA19MShares$1.12 Billion0.03% of portfolio
-
Primecap Management CO Pasadena, CA17.8MShares$1.05 Billion1.06% of portfolio
-
Dodge & Cox San Francisco, CA15MShares$885 Million0.65% of portfolio
-
Viking Global Investors LP10.8MShares$639 Million2.55% of portfolio
About BIOMARIN PHARMACEUTICAL INC
- Ticker BMRN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,824,000
- Market Cap $11B
- Description
- BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...